{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:33:53Z","timestamp":1776119633248,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC. Oncolytic virotherapy using enteroviruses has emerged as a promising anticancer strategy. To identify a novel, potent virotherapy with an improved safety profile, we assessed the oncolytic activity of 28 enteroviral strains and focused on coxsackievirus A11 (CVA11). CVA11 infection caused extensive oncolytic activity in all three of the examined human NSCLC cell lines, with high intercellular adhesion molecule-1 (ICAM-1) expression associated with greater CVA11-induced cytotoxicity. In vitro inhibition analysis using a pan-caspase inhibitor and western blot detection of cleaved poly (ADP-ribose) polymerase (PARP) indicated that apoptosis partly contributed to CVA11-driven cytotoxicity. CVA11 infection-induced immunogenic cell death in vitro was strongly suggested by substantial calreticulin expression and release of high mobility group box-1 protein (HMGB1). Moreover, in vivo treatment of human NSCLC xenografts with intratumoral CVA11 injection caused complete tumor regression in all treated mice, without significant weight loss. Our findings indicate that novel oncolytic virotherapy utilizing CVA11 may be less toxic and more effective than current treatments for human NSCLC, thus warranting further investigation in clinical trial settings, especially in combination with immunotherapy.<\/jats:p>","DOI":"10.1038\/s41598-023-33126-x","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:04:27Z","timestamp":1681293867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Akira","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Soda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzaburo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"33126_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"33126_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.resmer.2019.10.001","volume":"77","author":"O Molinier","year":"2020","unstructured":"Molinier, O. et al. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients. Respir. Med. Res. 77, 46\u201354. https:\/\/doi.org\/10.1016\/j.resmer.2019.10.001 (2020).","journal-title":"Respir. Med. Res."},{"key":"33126_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1515\/hsz-2017-0103","volume":"398","author":"D Masemann","year":"2017","unstructured":"Masemann, D., Boergeling, Y. & Ludwig, S. Employing RNA viruses to fight cancer: Novel insights into oncolytic virotherapy. Biol. Chem. 398, 891\u2013909. https:\/\/doi.org\/10.1515\/hsz-2017-0103 (2017).","journal-title":"Biol. Chem."},{"key":"33126_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02830-x","author":"C Tang","year":"2022","unstructured":"Tang, C. et al. Oncolytic viral vectors in the era of diversified cancer therapy: From preclinical to clinical. Clin. Transl. Oncol. https:\/\/doi.org\/10.1007\/s12094-022-02830-x (2022).","journal-title":"Clin. Transl. Oncol."},{"key":"33126_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/v6072531","volume":"6","author":"CC Stobart","year":"2014","unstructured":"Stobart, C. C. & Moore, M. L. RNA virus reverse genetics and vaccine design. Viruses 6, 2531\u20132550. https:\/\/doi.org\/10.3390\/v6072531 (2014).","journal-title":"Viruses"},{"key":"33126_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ymthe.2020.04.005","volume":"28","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Enterovirus A71 oncolysis of malignant gliomas. Mol. Ther. 28, 1533\u20131546. https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.005 (2020).","journal-title":"Mol. Ther."},{"key":"33126_CR7","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.21873\/anticanres.12963","volume":"38","author":"B Wang","year":"2018","unstructured":"Wang, B. et al. A novel combination therapy for human oxaliplatin-resistant colorectal cancer using oxaliplatin and coxsackievirus A11. Anticancer Res. 38, 6121\u20136126. https:\/\/doi.org\/10.21873\/anticanres.12963 (2018).","journal-title":"Anticancer Res."},{"key":"33126_CR8","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1038\/emi.2016.73","volume":"5","author":"Q Mao","year":"2016","unstructured":"Mao, Q., Wang, Y., Bian, L., Xu, M. & Liang, Z. EV-A71 vaccine licensure: A first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg. Microbes Infect. 5, e75. https:\/\/doi.org\/10.1038\/emi.2016.73 (2016).","journal-title":"Emerg. Microbes Infect."},{"key":"33126_CR9","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","volume":"72","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto, S. et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 72, 2609\u20132621. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3185 (2012).","journal-title":"Cancer Res."},{"key":"33126_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S56322","volume":"3","author":"S Bradley","year":"2014","unstructured":"Bradley, S. et al. Applications of coxsackievirus A21 in oncology. Oncolytic Virother 3, 47\u201355. https:\/\/doi.org\/10.2147\/OV.S56322 (2014).","journal-title":"Oncolytic Virother"},{"key":"33126_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","volume":"9","author":"NE Annels","year":"2018","unstructured":"Annels, N. E. et al. Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol. Ther. Oncolytics 9, 1\u201312. https:\/\/doi.org\/10.1016\/j.omto.2018.02.001 (2018).","journal-title":"Mol. Ther. Oncolytics"},{"key":"33126_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/nm.1776","volume":"14","author":"EJ Kelly","year":"2008","unstructured":"Kelly, E. J., Hadac, E. M., Greiner, S. & Russell, S. J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14, 1278\u20131283. https:\/\/doi.org\/10.1038\/nm.1776 (2008).","journal-title":"Nat. Med."},{"key":"33126_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/mt.2009.296","volume":"18","author":"X Meng","year":"2010","unstructured":"Meng, X. et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol. Ther. 18, 544\u2013551. https:\/\/doi.org\/10.1038\/mt.2009.296 (2010).","journal-title":"Mol. Ther."},{"key":"33126_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491. https:\/\/doi.org\/10.1038\/onc.2009.356 (2010).","journal-title":"Oncogene"},{"key":"33126_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1006\/viro.1995.1450","volume":"212","author":"T Pulli","year":"1995","unstructured":"Pulli, T., Koskimies, P. & Hyypi\u00e4, T. Molecular comparison of coxsackie A virus serotypes. Virology 212, 30\u201338. https:\/\/doi.org\/10.1006\/viro.1995.1450 (1995).","journal-title":"Virology"},{"key":"33126_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1128\/JVI.71.1.785-789.1997","volume":"71","author":"DR Shafren","year":"1997","unstructured":"Shafren, D. R., Dorahy, D. J., Greive, S. J., Burns, G. F. & Barry, R. D. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J. Virol. 71, 785\u2013789. https:\/\/doi.org\/10.1128\/JVI.71.1.785-789.1997 (1997).","journal-title":"J. Virol."},{"key":"33126_CR17","doi-asserted-by":"publisher","first-page":"9844","DOI":"10.1128\/JVI.71.12.9844-9848.1997","volume":"71","author":"DR Shafren","year":"1997","unstructured":"Shafren, D. R., Williams, D. T. & Barry, R. D. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J. Virol. 71, 9844\u20139848. https:\/\/doi.org\/10.1128\/JVI.71.12.9844-9848.1997 (1997).","journal-title":"J. Virol."},{"key":"33126_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-0-387-39978-2_10","volume":"593","author":"L Quintieri","year":"2007","unstructured":"Quintieri, L., Fantin, M. & Vizler, C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv. Exp. Med. Biol. 593, 95\u2013104. https:\/\/doi.org\/10.1007\/978-0-387-39978-2_10 (2007).","journal-title":"Adv. Exp. Med. Biol."},{"key":"33126_CR19","doi-asserted-by":"publisher","first-page":"43201","DOI":"10.1863\/oncotarget.17970","volume":"8","author":"Y Liao","year":"2017","unstructured":"Liao, Y. et al. RIP1 is a central signaling protein in regulation of TNF-\u03b1\/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection. Oncotarget 8, 43201\u201343217. https:\/\/doi.org\/10.1863\/oncotarget.17970 (2017).","journal-title":"Oncotarget"},{"key":"33126_CR20","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene 40, 4783\u20134795. https:\/\/doi.org\/10.1038\/s41388-021-01869-4 (2021).","journal-title":"Oncogene"},{"key":"33126_CR21","doi-asserted-by":"publisher","first-page":"E961","DOI":"10.1073\/pnas.1613305114","volume":"114","author":"SA Conos","year":"2017","unstructured":"Conos, S. A. et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc. Natl. Acad. Sci. U S A 114, E961\u2013E969. https:\/\/doi.org\/10.1073\/pnas.1613305114 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"33126_CR22","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","volume":"67","author":"RM Diaz","year":"2007","unstructured":"Diaz, R. M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840\u20132848. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3974 (2007).","journal-title":"Cancer Res."},{"key":"33126_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991\u20131045. https:\/\/doi.org\/10.1146\/annurev.iy.12.040194.005015 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"33126_CR24","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","volume":"14","author":"RJ Prestwich","year":"2008","unstructured":"Prestwich, R. J. et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14, 7358\u20137366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0831 (2008).","journal-title":"Clin. Cancer Res."},{"key":"33126_CR25","first-page":"4665","volume":"34","author":"EA Kotteas","year":"2014","unstructured":"Kotteas, E. A. et al. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: Implications for disease progression and prognosis. Anticancer Res. 34, 4665\u20134672 (2014).","journal-title":"Anticancer Res."},{"key":"33126_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.surg.2007.01.016","volume":"141","author":"CL Roland","year":"2007","unstructured":"Roland, C. L., Harken, A. H., Sarr, M. G. & Barnett, C. C. ICAM-1 expression determines malignant potential of cancer. Surgery 141, 705\u2013707. https:\/\/doi.org\/10.1016\/j.surg.2007.01.016 (2007).","journal-title":"Surgery"},{"key":"33126_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275\u2013284. https:\/\/doi.org\/10.1038\/nrc1590 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"33126_CR28","doi-asserted-by":"publisher","first-page":"e111174","DOI":"10.1371\/journal.pone.0111174","volume":"9","author":"Z Li","year":"2014","unstructured":"Li, Z. et al. Coxsackievirus A16 infection induces neural cell and non-neural cell apoptosis in vitro. PLoS ONE 9, e111174. https:\/\/doi.org\/10.1371\/journal.pone.0111174 (2014).","journal-title":"PLoS ONE"},{"key":"33126_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683\u2013687. https:\/\/doi.org\/10.1038\/s41586-019-1770-6 (2019).","journal-title":"Nature"},{"key":"33126_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau0417","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K., Aspromonte, S., Zloza, A., Rabkin, S. D. & Kaufman, H. L. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau0417 (2018).","journal-title":"Sci. Transl. Med."},{"key":"33126_CR31","doi-asserted-by":"publisher","first-page":"e1376156","DOI":"10.1080\/2162402X.2017.1376156","volume":"7","author":"X Yan","year":"2017","unstructured":"Yan, X. et al. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology 7, e1376156. https:\/\/doi.org\/10.1080\/2162402X.2017.1376156 (2017).","journal-title":"Oncoimmunology"},{"key":"33126_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41426-018-0186-y","volume":"7","author":"Q Mao","year":"2018","unstructured":"Mao, Q. et al. A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5. Emerg. Microbes Infect. 7, 185. https:\/\/doi.org\/10.1038\/s41426-018-0186-y (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"33126_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bjc.1998.130","volume":"77","author":"A Grothey","year":"1998","unstructured":"Grothey, A., Heistermann, P., Philippou, S. & Voigtmann, R. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: Correlation with histological expression of ICAM-1 and tumour stage. Br. J. Cancer 77, 801\u2013807. https:\/\/doi.org\/10.1038\/bjc.1998.130 (1998).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33126-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:10:37Z","timestamp":1681294237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33126-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33126"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33126-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KT's Laboratory has been financially supported by Neo Pharma Japan Co., Ltd. KT is a scientific advisor and a major stockholder of NPT Co., Ltd, and a minor stockholder of Oncolys BioPharma Inc, Shinnihonseiyaku Co., Ltd., NPT Co., Ltd, and SymBio Pharmaceuticals Co., Ltd. HI receives remuneration from Jocavio Inc. as an advisor, is a stockholder in Jocavio Inc. SM is a stockholder of NPT Co., Ltd. KT, HI and SM hold a patent on CVA11 [PCT\/UP2O13A061686, PCT\/JP2013\/061686]. The other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5924"}}